The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.00
Bid: 9.60
Ask: 11.40
Change: 0.60 (6.38%)
Spread: 1.80 (18.75%)
Open: 9.20
High: 10.00
Low: 9.20
Prev. Close: 9.40
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

22 Aug 2019 11:42

RNS Number : 9401J
e-Therapeutics plc
22 August 2019
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

 

e-Therapeutics PLC

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation: iii

Rupert Labrum

4. Full name of shareholder(s)

(if different from 3.): iv

5. Date of the transaction and date on which the threshold is crossed or reached: v

16/08/2019

6. Date on which issuer notified:

20/08/2019

7. Threshold(s) that is/are crossed or reached: vi, vii

 

4.00%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

Situation previous to the triggering transaction

 

Resulting situation after the triggering transaction

 

if possible using

the ISIN CODE

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00B2823H99

 

12015000

 

12015000

 

12015000

 

12015000

 

4.46%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial

Expiration

Exercise/

Number of voting

% of voting

instrument

date xiii

Conversion

rights that may be

rights

Period xiv

acquired if the

instrument is

exercised/

converted.

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights

xix, xx

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1201500

4.46%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

 

 

 

 

 

 

 

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

 

13. Additional information:

14. Contact name:

Rupert Labrum

15. Contact telephone number:

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLEAEPAAAKNEFF
Date   Source Headline
14th Feb 20137:00 amRNSDirector/PDMR Shareholding
12th Feb 20134:08 pmRNSDirector/PDMR Shareholding
11th Feb 20133:38 pmRNSDirector/PDMR Shareholding
11th Feb 20137:00 amBUSe-Therapeutics to raise £40 million to advance lead cancer drug and exploit network pharmacology platform
8th Jan 20131:07 pmRNSHolding(s) in Company
18th Dec 20127:00 amBUSClinical Trial Update (ETS2101)
14th Nov 20123:30 pmRNSDirector/PDMR Shareholding
8th Nov 20126:01 pmRNSDirector/PDMR Shareholding
26th Oct 201210:25 amRNSDirector/PDMR Shareholding
23rd Oct 20125:23 pmRNSDirector/PDMR Shareholding
22nd Oct 20127:00 amBUSInterim Results for the six months ended 31 July 2012
2nd Oct 20128:57 amRNSDirector/PDMR Shareholding
25th Sep 20124:19 pmRNSDirector/PDMR Shareholding
12th Sep 20127:00 amBUSe-Therapeutics starts second phase I cancer trial of ETS2101
4th Sep 201211:00 amRNSNotice of Interim Results
6th Aug 20122:25 pmRNSAdditional Listing and Directors' Shareholdings
2nd Aug 20123:35 pmRNSAdditional Listing
31st Jul 20121:06 pmRNSResult of AGM
18th Jul 20125:14 pmRNSHolding(s) in Company
6th Jul 20122:08 pmBUSDirector/PDMR Shareholding
29th Jun 20121:03 pmRNSAnnual Financial Report
19th Jun 20127:00 amBUSe-Therapeutics' ETS2101 enters phase I clinical trial in brain cancer
22nd May 20127:03 amBUSe-Therapeutics' Preliminary Results for the Year Ended 31 January 2012
10th May 20127:00 amRNSNotice of Results
4th May 20126:00 pmRNSDirector/PDMR Shareholding
17th Apr 20123:55 pmRNSChange of Registered Office
29th Mar 20127:00 amBUSPhase I clinical trials of cancer drug ETS2101 approved by regulators
14th Mar 20125:59 pmRNSDirector/PDMR Shareholding
27th Feb 20127:00 amBUSPrime Minister Opens e-Therapeutics' Drug Discovery Centre near Oxford
8th Feb 20122:00 pmBUSe-Therapeutics to Present at The 14th Annual BIO CEO & Investor Conference
7th Feb 20128:41 amRNSHolding(s) in Company
6th Feb 20127:00 amBUSDirectorate Change
9th Jan 20122:00 pmBUSe-Therapeutics outlines goals for 2012 and announces presentation at Biotech Showcase Conference
30th Nov 20113:45 pmRNSDirector/PDMR Shareholding
27th Oct 201110:21 amRNSDirector/PDMR Shareholding
19th Oct 20117:00 amRNSInterim Results for the six months to 31 July 2011
26th Sep 20117:00 amRNSPatent for 'Power Behind the Throne'
21st Sep 20119:00 amRNSNotice of Interim Results
12th Sep 20111:06 pmRNSResult of AGM
17th Aug 20114:19 pmRNSDirector/PDMR Shareholding
15th Aug 20112:16 pmRNSDirector/PDMR Shareholding
9th Aug 201112:40 pmRNSDirector/PDMR Shareholding
28th Jul 201110:00 amRNSAnnual Financial Report
28th Jul 20117:30 amRNSDirector/PDMR Shareholding
25th Jul 20117:00 amRNSPreliminary Results and Business Update
29th Jun 20112:38 pmRNSNotice of Results
13th Jun 20117:00 amRNSDirectorate Change
6th Jun 20114:34 pmRNSAdditional Listing
24th May 20116:30 pmRNSDirector/PDMR Shareholding
23rd May 20115:59 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.